Abstract

BackgroundConventional renal cell carcinoma (cRCC) accounts for most of the deaths due to kidney cancer. Tumor stage, grade, and patient performance status are used currently to predict survival after surgery. Our goal was to identify gene expression features, using comprehensive gene expression profiling, that correlate with survival.Methods and FindingsGene expression profiles were determined in 177 primary cRCCs using DNA microarrays. Unsupervised hierarchical clustering analysis segregated cRCC into five gene expression subgroups. Expression subgroup was correlated with survival in long-term follow-up and was independent of grade, stage, and performance status. The tumors were then divided evenly into training and test sets that were balanced for grade, stage, performance status, and length of follow-up. A semisupervised learning algorithm (supervised principal components analysis) was applied to identify transcripts whose expression was associated with survival in the training set, and the performance of this gene expression-based survival predictor was assessed using the test set. With this method, we identified 259 genes that accurately predicted disease-specific survival among patients in the independent validation group (p < 0.001). In multivariate analysis, the gene expression predictor was a strong predictor of survival independent of tumor stage, grade, and performance status (p < 0.001).ConclusionscRCC displays molecular heterogeneity and can be separated into gene expression subgroups that correlate with survival after surgery. We have identified a set of 259 genes that predict survival after surgery independent of clinical prognostic factors.

Highlights

  • Our goal was to identify gene expression features, using comprehensive gene expression profiling, that correlate with survival

  • Conclusions Conventional renal cell carcinoma (cRCC) displays molecular heterogeneity and can be separated into gene expression subgroups that correlate with survival after surgery

  • Half of the patients diagnosed with renal cell carcinoma (RCC) succumb to their disease, and RCC accounts for 95,000 deaths per year worldwide [1]

Read more

Summary

Introduction

Half of the patients diagnosed with renal cell carcinoma (RCC) succumb to their disease, and RCC accounts for 95,000 deaths per year worldwide [1]. Conventional renal cell carcinoma (cRCC) accounts for approximately 75% of all RCC and accounts for the majority of kidney cancer mortality. Several prognostic algorithms have been developed that incorporate tumor stage, grade, and patient performance status, and they predict survival better than stage alone [5,6,7]. Based on these algorithms, fewer radiographic imaging and blood tests have been proposed for patients predicted to have a low risk of recurrence after surgery, and adjuvant therapy has been suggested for highrisk patients. Conventional renal cell carcinoma (cRCC) accounts for most of the deaths due to kidney cancer. This larger study looked systematically for variations in gene expression that were correlated with the clinical heterogeneity of cRCCs

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.